Meta-analysis of Vegetarian Diets and Incident Cardiovascular Outcomes
Launched by UNIVERSITY OF TORONTO · Jul 25, 2018
Trial Information
Current as of May 11, 2025
Unknown status
Keywords
ClinConnect Summary
Background: Cardiovascular disease (CVD) is the number 1 cause of death worldwide, representing 31% of all deaths. Vegetarian and/or vegan dietary patterns have been shown in prospective cohort and cross-sectional studies to be associated with lower coronary heart disease and ischemic heart disease risk. Evidence from randomized controlled trials also suggest that vegetarian and vegan diets may be beneficial for cardiovascular disease risk factors, such as LDL cholesterol, weight, blood pressure and type 2 diabetes (glycemic control). Moreover, evidence from meta-analyses of prospective coh...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Prospective cohorts studies
- • Duration \>=1 year
- • Assessment of the exposure of vegetarian or vegan diet
- • Ascertainment of viable data by level of exposure
- Exclusion Criteria:
- • Ecological, cross-sectional, retrospective observational studies, clinical trials and non-human studies
- • Duration \< 1 year
- • No assessment of exposure of vegetarian/vegan diet
- • No ascertainment viable clinical outcome data by level of exposure
About University Of Toronto
The University of Toronto, a prestigious research institution, serves as a leading sponsor of clinical trials dedicated to advancing medical knowledge and improving patient care. With a commitment to innovation and excellence, the university fosters a collaborative environment that brings together multidisciplinary teams of experts in medicine, pharmacology, and public health. Through rigorous research methodologies and ethical standards, the University of Toronto aims to explore new therapies, assess treatment efficacy, and address critical health challenges, ultimately contributing to the global body of scientific knowledge and enhancing healthcare outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
John Sievenpiper, PhD, MD
Principal Investigator
University of Toronto
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials